Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 46 articles:
HTML format
Text format



Single Articles


    March 2017
  1. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Text format     Abstract available


    January 2017
  2. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available


  3. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


    June 2016
  4. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Text format     Abstract available


    January 2016
  5. GERBES AL
    Liver Cirrhosis and Kidney.
    Dig Dis. 2016;34:387-90.
    PubMed     Text format     Abstract available


  6. GARCIA-TSAO G
    Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
    Dig Dis. 2016;34:382-6.
    PubMed     Text format     Abstract available


  7. SAFFIOTI F, Pinzani M
    Development and Regression of Cirrhosis.
    Dig Dis. 2016;34:374-81.
    PubMed     Text format     Abstract available


  8. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Text format     Abstract available


  9. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Text format     Abstract available


  10. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Text format     Abstract available


  11. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Text format     Abstract available


  12. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Text format     Abstract available


  13. WU T, Wang P, Zhang T, Zheng J, et al
    Comparison of Two-Dimensional Shear Wave Elastography and Real-Time Tissue Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B.
    Dig Dis. 2016;34:640-649.
    PubMed     Text format     Abstract available


  14. NISHIDA N, Kono M, Minami T, Chishina H, et al
    Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.
    Dig Dis. 2016;34:632-639.
    PubMed     Text format     Abstract available


  15. SUGIMOTO K, Kim SK, Kim SR, Kobayashi M, et al
    Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.
    Dig Dis. 2016;34:627-631.
    PubMed     Text format     Abstract available


  16. HAGIWARA S, Nishida N, Watanabe T, Sakurai T, et al
    Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.
    Dig Dis. 2016;34:620-626.
    PubMed     Text format     Abstract available


  17. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Text format     Abstract available


  18. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Text format     Abstract available


  19. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  20. WEILER-NORMANN C, Lohse AW
    Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management.
    Dig Dis. 2016;34:334-9.
    PubMed     Text format     Abstract available


  21. ARNDTZ K, Hirschfield GM
    The Pathogenesis of Autoimmune Liver Disease.
    Dig Dis. 2016;34:327-33.
    PubMed     Text format     Abstract available


  22. DALTON HR, Webb GW, Norton BC, Woolson KL, et al
    Hepatitis E Virus: Time to Change the Textbooks.
    Dig Dis. 2016;34:308-16.
    PubMed     Text format     Abstract available


  23. BLUM HE
    History and Global Burden of Viral Hepatitis.
    Dig Dis. 2016;34:293-302.
    PubMed     Text format     Abstract available


  24. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Text format     Abstract available


    October 2015
  25. PISCAGLIA F, Iavarone M, Galassi M, Vavassori S, et al
    Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging.
    Dig Dis. 2015;33:735-744.
    PubMed     Text format     Abstract available


    September 2015
  26. SASAKI M, Nakanuma Y
    Serum Amyloid A-Positive Hepatocellular Neoplasm: A New Type of Tumor Arising in Patients with Advanced Alcoholic Disease.
    Dig Dis. 2015;33:648-654.
    PubMed     Text format     Abstract available


  27. YOPP AC, Choti MA
    Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Dig Dis. 2015;33:642-647.
    PubMed     Text format     Abstract available


    January 2015
  28. RIDLON JM, Kang DJ, Hylemon PB, Bajaj JS, et al
    Gut microbiota, cirrhosis, and alcohol regulate bile Acid metabolism in the gut.
    Dig Dis. 2015;33:338-45.
    PubMed     Text format     Abstract available


  29. BAILLY F, Pradat P, Virlogeux V, Zoulim F, et al
    Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Dig Dis. 2015;33:613-23.
    PubMed     Text format     Abstract available


  30. BOETTLER T, Thimme R
    Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
    Dig Dis. 2015;33:608-12.
    PubMed     Text format     Abstract available


  31. TRAUSSNIGG S, Kienbacher C, Halilbasic E, Rechling C, et al
    Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Dig Dis. 2015;33:598-607.
    PubMed     Text format     Abstract available


  32. WONG F
    Definition and Diagnosis of Acute Kidney Injury in Cirrhosis.
    Dig Dis. 2015;33:539-47.
    PubMed     Text format     Abstract available


  33. SOLA E, Gines P
    Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis.
    Dig Dis. 2015;33:534-8.
    PubMed     Text format     Abstract available


  34. PARES A
    Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Dig Dis. 2015;33 Suppl 2:125-33.
    PubMed     Text format     Abstract available


  35. JOPSON L, Jones DE
    Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management.
    Dig Dis. 2015;33 Suppl 2:109-14.
    PubMed     Text format     Abstract available


  36. CORRIGAN M, Hirschfield GM
    Aspects of the Pathophysiology of Primary Biliary Cirrhosis.
    Dig Dis. 2015;33 Suppl 2:102-8.
    PubMed     Text format     Abstract available


  37. SANYAL AJ
    Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Dig Dis. 2015;33:426-32.
    PubMed     Text format     Abstract available


  38. STEIB CJ, Schewe J, Gerbes AL
    Infection as a Trigger for Portal Hypertension.
    Dig Dis. 2015;33:570-6.
    PubMed     Text format     Abstract available


  39. DIREKZE S, Jalan R
    Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy.
    Dig Dis. 2015;33:562-9.
    PubMed     Text format     Abstract available


  40. CAVALLIN M, Fasolato S, Marenco S, Piano S, et al
    The Treatment of Hepatorenal Syndrome.
    Dig Dis. 2015;33:548-54.
    PubMed     Text format     Abstract available


  41. ABRALDES JG, Tandon P
    Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt - When and How?
    Dig Dis. 2015;33:524-33.
    PubMed     Text format     Abstract available


  42. FRIEDMAN SL
    Hepatic Fibrosis: Emerging Therapies.
    Dig Dis. 2015;33:504-7.
    PubMed     Text format     Abstract available


  43. HERKEL J
    Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Dig Dis. 2015;33 Suppl 2:70-4.
    PubMed     Text format     Abstract available


  44. VAN BUUREN HR, Lammers WJ, Harms MH, Hansen BE, et al
    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:118-24.
    PubMed     Text format     Abstract available


  45. POUPON R
    Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:115-7.
    PubMed     Text format     Abstract available


    January 2014
  46. WU T, Ren J, Cong SZ, Meng FK, et al
    Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study.
    Dig Dis. 2014;32:791-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: